Insider · CIK 0001416750
Henry A Fernandez
Files at MSCI (MSCI Inc.), RPRX (Royalty Pharma plc). First filing Dec 9, 2024, latest Jul 28, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MSCI: MSCI Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | MSCIbuy MSCI Inc. | $6.7M 12,400 shares | +1% | +8% from low-14% from high | |
| 50Moderate | MSCIbuy MSCI Inc. | $3.0M 5,300 shares | +0% | - | |
| 45Moderate | MSCIbuy MSCI Inc. | $1.8M 2,900 shares | +1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 24, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stock | +9,916 | $544.70 | $5.4M | 1,279,867 | Jul 28, 2025 |
| Jul 25, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stock | +23 | $546.40 | $13k | 1,279,890 | Jul 28, 2025 |
| Jul 25, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stock | +18 | $547.49 | $9,855 | 1,279,908 | Jul 28, 2025 |
| Jul 25, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stock | +43 | $550.41 | $24k | 1,279,951 | Jul 28, 2025 |
| Jul 24, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stockindirect: By Fernandez 2007 Children's Trust | +2,400 | $535.11 | $1.3M | 332,779 | Jul 28, 2025 |
| Jun 30, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +1,064 | $35.24 | $37k | 65,324 | Jun 30, 2025 |
| May 13, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +7,614 | $0.00 | $0 | 64,260 | May 14, 2025 |
| Mar 31, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +1,141 | $32.87 | $37k | 56,646 | Apr 1, 2025 |
| Feb 24, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stock | +500 | $569.86 | $285k | 1,265,151 | Feb 25, 2025 |
| Feb 24, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stock | +4,700 | $574.98 | $2.7M | 1,269,851 | Feb 25, 2025 |
| Feb 24, 2025 | MSCI MSCI Inc. | POpen-market purchase Common Stock | +100 | $575.66 | $58k | 1,269,951 | Feb 25, 2025 |
| Feb 6, 2025 | MSCI MSCI Inc. | AGrant or award Common Stock | +58,370 | $0.00 | $0 | 1,296,930 | Feb 10, 2025 |
| Feb 6, 2025 | MSCI MSCI Inc. | FTax withholding Common Stock | -32,279 | $587.48 | $19M | 1,264,651 | Feb 10, 2025 |
| Jan 31, 2025 | MSCI MSCI Inc. | AGrant or award Premium option to purchase common stockderivative | +36,846 | $0.00 | $0 | 36,846 | Feb 4, 2025 |
| Jan 31, 2025 | MSCI MSCI Inc. | AGrant or award Premium option to purchase common stockderivative | +40,780 | $0.00 | $0 | 40,780 | Feb 4, 2025 |
| Jan 31, 2025 | MSCI MSCI Inc. | AGrant or award Premium option to purchase common stockderivative | +44,920 | $0.00 | $0 | 44,920 | Feb 4, 2025 |
| Jan 27, 2025 | MSCI MSCI Inc. | AGrant or award Option to purchase common stockderivative | +29,564 | $0.00 | $0 | 29,564 | Jan 29, 2025 |
| Dec 31, 2024 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Shares | +1,503 | $24.94 | $37k | 55,505 | Jan 2, 2025 |
| Dec 5, 2024 | MSCI MSCI Inc. | POpen-market purchase Common Stockindirect: By Fernandez 2007 Children's Trust | +600 | $610.00 | $366k | 328,079 | Dec 9, 2024 |
| Dec 5, 2024 | MSCI MSCI Inc. | POpen-market purchase Common Stockindirect: By Fernandez 2007 Children's Trust | +1,807 | $613.38 | $1.1M | 329,886 | Dec 9, 2024 |
| Dec 5, 2024 | MSCI MSCI Inc. | POpen-market purchase Common Stockindirect: By Fernandez 2007 Children's Trust | +493 | $614.08 | $303k | 330,379 | Dec 9, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.